Comparative Effectiveness and Safety of a Catheterization Laboratory-Only Eptifibatide Dosing Strategy in Patients Undergoing Percutaneous Coronary Intervention

摘要

Background-Eptifibatide, a small-molecule glycoprotein IIb/IIIa inhibitor, is conventionally administered as a bolus plus infusion. A growing number of clinicians are using a strategy of catheterization laboratory-only eptifibatide (an off-label use) as procedural pharmacotherapy for patients undergoing percutaneous coronary intervention although the comparative effectiveness of this approach is unknown.